Formulation Stabilization and Disaggregation of Bevacizumab, Ranibizumab and Aflibercept in Dilute Solutions
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-904X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Formulation Stabilization and Disaggregation of Bevacizumab, Ranibizumab and Aflibercept in Dilute Solutions ; volume:35 ; number:4 ; day:28 ; month:2 ; year:2018 ; pages:1-15 ; date:4.2018
Pharmaceutical research ; 35, Heft 4 (28.2.2018), 1-15, 4.2018
- Urheber
-
Giannos, Steven A.
- Beteiligte Personen und Organisationen
-
Kraft, Edward R.
Zhao, Zhen-Yang
Merkley, Kevin H.
Cai, Jiyang
SpringerLink (Online service)
- DOI
-
10.1007/s11095-018-2368-7
- URN
-
urn:nbn:de:1111-2018052938
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 15.08.2025, 07:24 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Giannos, Steven A.
- Kraft, Edward R.
- Zhao, Zhen-Yang
- Merkley, Kevin H.
- Cai, Jiyang
- SpringerLink (Online service)
Ähnliche Objekte (12)
Hydrodynamic Radii of Ranibizumab, Aflibercept and Bevacizumab Measured by Time-Resolved Phosphorescence Anisotropy
Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab
Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD
Intravitreal aflibercept and ranibizumab for pachychoroid neovasculopathy
Photokinetic Drug Delivery: Near infrared (NIR) Induced Permeation Enhancement of Bevacizumab, Ranibizumab and Aflibercept through Human Sclera
How Successful is Switching from Bevacizumab or Ranibizumab to Aflibercept in Age-Related Macular Degeneration? A Systematic Overview
Erratum für: Das klinische Ergebnis eines Therapiewechsels von Ranibizumab und/oder Bevacizumab zu Aflibercept bei neovaskulärer altersabhängiger Makuladegeneration (AMD)
Auswirkungen von intravitrealem Ranibizumab, Aflibercept und Bevacizumab auf die Dicke der retinalen Ganglienzell- und Nervenfaserschicht bei neovaskulärer altersbedingter Makuladegeneration
Comparison Between Ranibizumab Biosimilar, Innovator Ranibizumab and Bevacizumab in a Real-World Situation
Conversion back to bevacizumab or ranibizumab for recurrent neovascular activity with aflibercept in age-related macular degeneration: a case series
Untersuchungen zur Effizienz von Aflibercept, Ranibizumab und Bevacizumab bei der feuchten Form der altersbedingten Makuladegeneration mit einem in vitro Organkulturmodell
The efficacy and ocular safety following aflibercept, conbercept, ranibizumab, bevacizumab, and laser for retinopathy of prematurity: a systematic review and meta-analysis
Hydrodynamic Radii of Ranibizumab, Aflibercept and Bevacizumab Measured by Time-Resolved Phosphorescence Anisotropy
Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab
Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD
Intravitreal aflibercept and ranibizumab for pachychoroid neovasculopathy
Photokinetic Drug Delivery: Near infrared (NIR) Induced Permeation Enhancement of Bevacizumab, Ranibizumab and Aflibercept through Human Sclera
How Successful is Switching from Bevacizumab or Ranibizumab to Aflibercept in Age-Related Macular Degeneration? A Systematic Overview
Erratum für: Das klinische Ergebnis eines Therapiewechsels von Ranibizumab und/oder Bevacizumab zu Aflibercept bei neovaskulärer altersabhängiger Makuladegeneration (AMD)
Auswirkungen von intravitrealem Ranibizumab, Aflibercept und Bevacizumab auf die Dicke der retinalen Ganglienzell- und Nervenfaserschicht bei neovaskulärer altersbedingter Makuladegeneration
Comparison Between Ranibizumab Biosimilar, Innovator Ranibizumab and Bevacizumab in a Real-World Situation
Conversion back to bevacizumab or ranibizumab for recurrent neovascular activity with aflibercept in age-related macular degeneration: a case series
Untersuchungen zur Effizienz von Aflibercept, Ranibizumab und Bevacizumab bei der feuchten Form der altersbedingten Makuladegeneration mit einem in vitro Organkulturmodell
The efficacy and ocular safety following aflibercept, conbercept, ranibizumab, bevacizumab, and laser for retinopathy of prematurity: a systematic review and meta-analysis
Hydrodynamic Radii of Ranibizumab, Aflibercept and Bevacizumab Measured by Time-Resolved Phosphorescence Anisotropy
Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab
Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD
Intravitreal aflibercept and ranibizumab for pachychoroid neovasculopathy
Photokinetic Drug Delivery: Near infrared (NIR) Induced Permeation Enhancement of Bevacizumab, Ranibizumab and Aflibercept through Human Sclera
How Successful is Switching from Bevacizumab or Ranibizumab to Aflibercept in Age-Related Macular Degeneration? A Systematic Overview
Erratum für: Das klinische Ergebnis eines Therapiewechsels von Ranibizumab und/oder Bevacizumab zu Aflibercept bei neovaskulärer altersabhängiger Makuladegeneration (AMD)
Auswirkungen von intravitrealem Ranibizumab, Aflibercept und Bevacizumab auf die Dicke der retinalen Ganglienzell- und Nervenfaserschicht bei neovaskulärer altersbedingter Makuladegeneration
Comparison Between Ranibizumab Biosimilar, Innovator Ranibizumab and Bevacizumab in a Real-World Situation
Conversion back to bevacizumab or ranibizumab for recurrent neovascular activity with aflibercept in age-related macular degeneration: a case series
Untersuchungen zur Effizienz von Aflibercept, Ranibizumab und Bevacizumab bei der feuchten Form der altersbedingten Makuladegeneration mit einem in vitro Organkulturmodell